drugset

drugset / Trial / NCT00095524

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524 ↗

Phase 3 Completed 300 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.

Timeline

Start: 2004-03
Primary completion: 2006-08
Completion: 2006-08

Outcome

Met primary endpoint

paper At week 16, weight decreased significantly with aripiprazole versus olanzapine (-1.8 vs. +1.41 kg; p < .001). PMID 18605811 ↗

Publications

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008 Jul;69(7):1046-56. doi: 10.4088/jcp.v69n0702.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aripiprazole	Other / unclassified	—	—

Indications